Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : Finlabo SIM Spa

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sanofi SA announces positive phase 3 results for Toujeo

Saturday, 14 Jun 2014 01:01pm EDT 

Sanofi SA:Says that, in a pooled analysis, investigational therapy Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia).At any time of day, including night-time events, compared with Lantus(R) (insulin glargine [rDNA origin] injection, 100 U/mL).Pooled analysis comprised data from three differing type 2 patient populations.In this analysis, more pronounced, significant reductions in low blood sugar rates at any time of day, including nighttime, were observed with Toujeo during the 8-week titration period when compared with Lantus. 

Company Quote

-0.07 -0.08%
9 Oct 2015